Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)
Today's Latest Price: $58.00 USD
Updated Jul 9 4:00pm
Add HZNP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 213 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
HZNP Stock Summary
- Horizon Therapeutics Public Ltd Co's market capitalization of $11,210,138,020 is ahead of 86.64% of US-listed equities.
- Price to trailing twelve month operating cash flow for HZNP is currently 36.45, higher than 90.12% of US stocks with positive operating cash flow.
- HZNP's price/sales ratio is 8.15; that's higher than the P/S ratio of 84.97% of US stocks.
- If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be AKAM, TECH, MTCH, QUOT, and LNTH.
- Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Stock Price Chart Technical Analysis Charts
HZNP Price/Volume Stats
| Current price | $58.00 | 52-week high | $59.21 |
| Prev. close | $58.76 | 52-week low | $22.81 |
| Day low | $56.89 | Volume | 1,905,287 |
| Day high | $59.21 | Avg. volume | 2,210,864 |
| 50-day MA | $48.46 | Dividend yield | N/A |
| 200-day MA | $36.16 | Market Cap | 11.07B |
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $58.00 | $228.98 | 300% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 75th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 301.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
- In the past 5.5 years, Horizon Therapeutics Public Ltd Co has a compound free cash flow growth rate of 1%; that's higher than 87.84% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 11% of the company's capital (with equity being the remaining amount). Approximately only 23.51% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 111 -- greater than 97.14% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 292% |
| 1% | 296% |
| 2% | 300% |
| 3% | 304% |
| 4% | 308% |
| 5% | 311% |
Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See LXRX, CI, MYL, AMEH, and CVS.
Loading social stream, please wait...